Altaris Clears Antitrust Hurdle in $X Billion Simulations Plus Acquisition
Event summary
- Simulations Plus cleared the HSR waiting period for its acquisition by Altaris.
- Transaction remains subject to shareholder approval and French regulatory clearance.
- Expected close in the second half of 2026.
- Altaris manages $9+ billion in equity capital.
The big picture
The acquisition reflects Altaris's focus on healthcare innovation, particularly in model-informed drug development. With $9+ billion in AUM, Altaris is positioning itself to consolidate the biopharma software space amid growing demand for AI-driven R&D efficiency. The deal underscores the strategic value of simulation platforms in accelerating drug discovery and commercialization.
What we're watching
- Regulatory Timing
- Whether French approvals will delay the second-half close.
- Shareholder Dynamics
- How Simulations Plus shareholders will vote on the deal.
- Integration Strategy
- Altaris's plans for scaling Simulations Plus's AI-accelerated drug development platform.
Related topics